{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:13:05Z","timestamp":1790230385097,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000867","name":"Commonwealth Scholarship Commission","doi-asserted-by":"publisher","award":["LKCS-2012-502"],"award-info":[{"award-number":["LKCS-2012-502"]}],"id":[{"id":"10.13039\/501100000867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000691","name":"Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008968","name":"National Research Council Sri Lanka","doi-asserted-by":"publisher","award":["18-030"],"award-info":[{"award-number":["18-030"]}],"id":[{"id":"10.13039\/100008968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\u03b2-Thalassaemia is one of the most common monogenic diseases with no effective cure in the majority of patients. Unbalanced production of \u03b1-globin in the presence of defective synthesis of \u03b2-globin is the primary mechanism for anaemia in \u03b2-thalassaemia. Clinical genetic data accumulated over three decades have clearly demonstrated that direct suppression of \u03b1-globin and induction of \u03b3-globin are effective in reducing the globin chain imbalance in erythroid cells hence improving the clinical outcome of patients with \u03b2-thalassaemia. Here, we show that the histone deacetylase inhibitor drug, vorinostat, in addition to its beneficial effects for patients with \u03b2-thalassaemia through induction of \u03b3-globin, has the potential to simultaneously suppress \u03b1-globin. We further show that vorinostat exhibits these synergistic beneficial effects in globin gene expression at nanomolar concentrations without perturbing erythroid expansion, viability, differentiation or the transcriptome. This new evidence will be helpful for the interpretation of existing clinical trials and future clinical studies that are directed towards finding a cure for \u03b2-thalassaemia using vorinostat.<\/jats:p>","DOI":"10.1038\/s41598-019-48204-2","type":"journal-article","created":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T10:03:15Z","timestamp":1565604195000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Synergistic silencing of \u03b1-globin and induction of \u03b3-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for \u03b2-thalassaemia"],"prefix":"10.1038","volume":"9","author":[{"given":"Sachith","family":"Mettananda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmani","family":"Yasara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,12]]},"reference":[{"key":"48204_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/j.1365-2141.2011.08742.x","volume":"154","author":"DJ Weatherall","year":"2011","unstructured":"Weatherall, D. J. The challenge of haemoglobinopathies in resource-poor countries. Br J Haematol 154, 736\u2013744, https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08742.x (2011).","journal-title":"Br J Haematol"},{"key":"48204_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0140-6736(11)60283-3","volume":"379","author":"DR Higgs","year":"2012","unstructured":"Higgs, D. R., Engel, J. D. & Stamatoyannopoulos, G. Thalassaemia. Lancet 379, 373\u2013383, https:\/\/doi.org\/10.1016\/S0140-6736(11)60283-3 (2012).","journal-title":"Lancet"},{"key":"48204_CR3","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1182\/blood-2010-01-251348","volume":"115","author":"DJ Weatherall","year":"2010","unstructured":"Weatherall, D. J. The inherited diseases of hemoglobin are an emerging global health burden. Blood 115, 4331\u20134336, https:\/\/doi.org\/10.1182\/blood-2010-01-251348 (2010).","journal-title":"Blood"},{"issue":"4","key":"48204_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.blre.2018.02.001","volume":"32","author":"Maria Domenica Cappellini","year":"2018","unstructured":"Cappellini, M. D., Porter, J. B., Viprakasit, V. & Taher, A. T. A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? Blood reviews, https:\/\/doi.org\/10.1016\/j.blre.2018.02.001 (2018).","journal-title":"Blood Reviews"},{"key":"48204_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.hoc.2017.11.010","volume":"32","author":"JB Porter","year":"2018","unstructured":"Porter, J. B. & Garbowski, M. W. Interaction of Transfusion and Iron Chelation in Thalassemias. Hematology\/oncology clinics of North America 32, 247\u2013259, https:\/\/doi.org\/10.1016\/j.hoc.2017.11.010 (2018).","journal-title":"Hematology\/oncology clinics of North America"},{"key":"48204_CR6","doi-asserted-by":"publisher","first-page":"e27643","DOI":"10.1002\/pbc.27643","volume":"66","author":"S Mettananda","year":"2019","unstructured":"Mettananda, S. et al. Blood transfusion therapy for beta-thalassemia major and hemoglobin E beta-thalassemia: Adequacy, trends, and determinants in Sri Lanka. Pediatric blood & cancer 66, e27643, https:\/\/doi.org\/10.1002\/pbc.27643 (2019).","journal-title":"Pediatric blood & cancer"},{"key":"48204_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-018-3634-9","volume":"11","author":"T Suriapperuma","year":"2018","unstructured":"Suriapperuma, T., Peiris, R., Mettananda, C., Premawardhena, A. & Mettananda, S. Body iron status of children and adolescents with transfusion dependent beta-thalassaemia: trends of serum ferritin and associations of optimal body iron control. BMC Res Notes 11, 547, https:\/\/doi.org\/10.1186\/s13104-018-3634-9 (2018).","journal-title":"BMC Res Notes"},{"key":"48204_CR8","unstructured":"Cappellini, M. D., Cohen, A., Porter, J., Taher, A. & Viprakasit, V. Guidelines for the management of transfusion dependent thalassaemia (TDT) 3rd Edition edn, (Thalassaemia International Federation, 2014)."},{"key":"48204_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","volume":"391","author":"AT Taher","year":"2018","unstructured":"Taher, A. T., Weatherall, D. J. & Cappellini, M. D. Thalassaemia. Lancet 391, 155\u2013167, https:\/\/doi.org\/10.1016\/S0140-6736(17)31822-6 (2018).","journal-title":"Lancet"},{"key":"48204_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.hoc.2017.11.003","volume":"32","author":"S Mettananda","year":"2018","unstructured":"Mettananda, S. & Higgs, D. R. Molecular Basis and Genetic Modifiers of Thalassemia. Hematology\/oncology clinics of North America 32, 177\u2013191, https:\/\/doi.org\/10.1016\/j.hoc.2017.11.003 (2018).","journal-title":"Hematology\/oncology clinics of North America"},{"key":"48204_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/nyas.12988","volume":"1368","author":"S Mettananda","year":"2016","unstructured":"Mettananda, S., Gibbons, R. J. & Higgs, D. R. Understanding alpha-globin gene regulation and implications for the treatment of beta-thalassemia. Annals of the New York Academy of Sciences 1368, 16\u201324, https:\/\/doi.org\/10.1111\/nyas.12988 (2016).","journal-title":"Annals of the New York Academy of Sciences"},{"key":"48204_CR12","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1182\/blood-2015-03-633594","volume":"125","author":"S Mettananda","year":"2015","unstructured":"Mettananda, S., Gibbons, R. J. & Higgs, D. R. alpha-Globin as a molecular target in the treatment of beta-thalassemia. Blood 125, 3694\u20133701, https:\/\/doi.org\/10.1182\/blood-2015-03-633594 (2015).","journal-title":"Blood"},{"key":"48204_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nm.3814","volume":"21","author":"VG Sankaran","year":"2015","unstructured":"Sankaran, V. G. & Weiss, M. J. Anemia: progress in molecular mechanisms and therapies. Nature medicine 21, 221\u2013230, https:\/\/doi.org\/10.1038\/nm.3814 (2015).","journal-title":"Nature medicine"},{"issue":"Suppl 1","key":"48204_CR14","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S0268-960X(12)70011-5","volume":"26","author":"SL Thein","year":"2012","unstructured":"Thein, S. L. The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. Blood reviews 26(Suppl 1), S35\u201339, https:\/\/doi.org\/10.1016\/S0268-960X(12)70011-5 (2012).","journal-title":"Blood reviews"},{"key":"48204_CR15","doi-asserted-by":"publisher","first-page":"e0206928","DOI":"10.1371\/journal.pone.0206928","volume":"13","author":"S Mettananda","year":"2018","unstructured":"Mettananda, S. et al. Anaemia among females in child-bearing age: Relative contributions, effects and interactions of alpha- and beta-thalassaemia. PloS one 13, e0206928, https:\/\/doi.org\/10.1371\/journal.pone.0206928 (2018).","journal-title":"PloS one"},{"key":"48204_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00479-7","volume":"8","author":"S Mettananda","year":"2017","unstructured":"Mettananda, S. et al. Editing an alpha-globin enhancer in primary human hematopoietic stem cells as a treatment for beta-thalassemia. Nature communications 8, 424, https:\/\/doi.org\/10.1038\/s41467-017-00479-7 (2017).","journal-title":"Nature communications"},{"key":"48204_CR17","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.3324\/haematol.2016.155655","volume":"102","author":"S Mettananda","year":"2017","unstructured":"Mettananda, S. et al. Selective silencing of alpha-globin by the histone demethylase inhibitor IOX1: a potentially new pathway for treatment of beta-thalassemia. Haematologica 102, e80\u2013e84, https:\/\/doi.org\/10.3324\/haematol.2016.155655 (2017).","journal-title":"Haematologica"},{"key":"48204_CR18","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1182\/blood-2012-06-292078","volume":"120","author":"DE Bauer","year":"2012","unstructured":"Bauer, D. E., Kamran, S. C. & Orkin, S. H. Reawakening fetal hemoglobin: prospects for new therapies for the beta-globin disorders. Blood 120, 2945\u20132953, https:\/\/doi.org\/10.1182\/blood-2012-06-292078 (2012).","journal-title":"Blood"},{"key":"48204_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nature15521","volume":"527","author":"MC Canver","year":"2015","unstructured":"Canver, M. C. et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 527, 192\u2013197, https:\/\/doi.org\/10.1038\/nature15521 (2015).","journal-title":"Nature"},{"key":"48204_CR20","doi-asserted-by":"publisher","first-page":"a011643","DOI":"10.1101\/cshperspect.a011643","volume":"3","author":"VG Sankaran","year":"2013","unstructured":"Sankaran, V. G. & Orkin, S. H. The switch from fetal to adult hemoglobin. Cold Spring Harbor perspectives in medicine 3, a011643, https:\/\/doi.org\/10.1101\/cshperspect.a011643 (2013).","journal-title":"Cold Spring Harbor perspectives in medicine"},{"key":"48204_CR21","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1128\/MCB.00714-14","volume":"34","author":"M Suzuki","year":"2014","unstructured":"Suzuki, M., Yamamoto, M. & Engel, J. D. Fetal globin gene repressors as drug targets for molecular therapies to treat the beta-globinopathies. Molecular and cellular biology 34, 3560\u20133569, https:\/\/doi.org\/10.1128\/MCB.00714-14 (2014).","journal-title":"Molecular and cellular biology"},{"key":"48204_CR22","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1182\/blood-2009-02-204990","volume":"115","author":"RP Hebbel","year":"2010","unstructured":"Hebbel, R. P. et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood 115, 2483\u20132490, https:\/\/doi.org\/10.1182\/blood-2009-02-204990 (2010).","journal-title":"Blood"},{"key":"48204_CR23","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/bjh.12814","volume":"165","author":"L Ronzoni","year":"2014","unstructured":"Ronzoni, L. et al. Modulation of gamma globin genes expression by histone deacetylase inhibitors: an in vitro study. Br J Haematol 165, 714\u2013721, https:\/\/doi.org\/10.1111\/bjh.12814 (2014).","journal-title":"Br J Haematol"},{"key":"48204_CR24","doi-asserted-by":"publisher","first-page":"12617","DOI":"10.1073\/pnas.1006774107","volume":"107","author":"JE Bradner","year":"2010","unstructured":"Bradner, J. E. et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America 107, 12617\u201312622, https:\/\/doi.org\/10.1073\/pnas.1006774107 (2010).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"48204_CR25","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/ijms18071414","volume":"18","author":"Tomas Eckschlager","year":"2017","unstructured":"Eckschlager, T., Plch, J., Stiborova, M. & Hrabeta, J. Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci 18, https:\/\/doi.org\/10.3390\/ijms18071414 (2017).","journal-title":"International Journal of Molecular Sciences"},{"key":"48204_CR26","doi-asserted-by":"publisher","first-page":"32918","DOI":"10.18632\/oncotarget.16464","volume":"8","author":"PH Goncalves","year":"2017","unstructured":"Goncalves, P. H. et al. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget 8, 32918\u201332929, https:\/\/doi.org\/10.18632\/oncotarget.16464 (2017).","journal-title":"Oncotarget"},{"key":"48204_CR27","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1182\/blood-2015-03-635391","volume":"125","author":"MM Okam","year":"2015","unstructured":"Okam, M. M. et al. Phase 1\/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea. Blood 125, 3668\u20133669, https:\/\/doi.org\/10.1182\/blood-2015-03-635391 (2015).","journal-title":"Blood"},{"key":"48204_CR28","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1124\/mol.107.036772","volume":"72","author":"A Mai","year":"2007","unstructured":"Mai, A. et al. Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Molecular pharmacology 72, 1111\u20131123, https:\/\/doi.org\/10.1124\/mol.107.036772 (2007).","journal-title":"Molecular pharmacology"},{"key":"48204_CR29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00280-013-2220-z","volume":"72","author":"M Iwamoto","year":"2013","unstructured":"Iwamoto, M. et al. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer chemotherapy and pharmacology 72, 493\u2013508, https:\/\/doi.org\/10.1007\/s00280-013-2220-z (2013).","journal-title":"Cancer chemotherapy and pharmacology"},{"key":"48204_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M Duvic","year":"2007","unstructured":"Duvic, M. et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109, 31\u201339, https:\/\/doi.org\/10.1182\/blood-2006-06-025999 (2007).","journal-title":"Blood"},{"key":"48204_CR31","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.bbagrm.2014.05.009","volume":"1839","author":"CC Thinnes","year":"2014","unstructured":"Thinnes, C. C. et al. Targeting histone lysine demethylases - progress, challenges, and the future. Biochimica et biophysica acta 1839, 1416\u20131432, https:\/\/doi.org\/10.1016\/j.bbagrm.2014.05.009 (2014).","journal-title":"Biochimica et biophysica acta"},{"key":"48204_CR32","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.1021\/jm800936s","volume":"51","author":"NR Rose","year":"2008","unstructured":"Rose, N. R. et al. Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. J Med Chem 51, 7053\u20137056, https:\/\/doi.org\/10.1021\/jm800936s (2008).","journal-title":"J Med Chem"},{"key":"48204_CR33","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1172\/jci70313","volume":"124","author":"P Chaurasia","year":"2014","unstructured":"Chaurasia, P., Gajzer, D. C., Schaniel, C., D\u2019Souza, S. & Hoffman, R. Epigenetic reprogramming induces the expansion of cord blood stem cells. The Journal of clinical investigation 124, 2378\u20132395, https:\/\/doi.org\/10.1172\/jci70313 (2014).","journal-title":"The Journal of clinical investigation"},{"key":"48204_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.exphem.2018.01.001","volume":"60","author":"S Mettananda","year":"2018","unstructured":"Mettananda, S. et al. Phenotypic and molecular characterization of a serum-free miniature erythroid differentiation system suitable for high-throughput screening and single-cell assays. Exp Hematol 60, 10\u201320, https:\/\/doi.org\/10.1016\/j.exphem.2018.01.001 (2018).","journal-title":"Exp Hematol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48204-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48204-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48204-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:30:44Z","timestamp":1671280244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48204-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,12]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48204"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48204-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,12]]},"assertion":[{"value":"27 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11649"}}